Disclosure of the status of a therapeutic treatment for Sanbexin sublingual tablets by the US-US Food and Drug Administration

NANJING, China, 16. September 2024 /PRNewswire/ — Am 2. September 2024 gab Simcere Pharmaceuticals Group Ltd. (2096.HK) can use Sanbexin Sublingual Tablets (Edaravone and Dexborneol Sublingual Tablets), an innovative drug against Schlaganfall, from the US-US Food and Drug Administration (FDA) with the status of a therapeutic treatment for the treatment of the harmful Schlaganfalls (AIS) hat. Sanbexin sublingual tablets are the first innovative drug in the world, which is used by the FDA as a therapy for the treatment of Schlaganfallen.

The treatment as Breakthrough Therapy (Breakthrough Therapy) originates from the best immunotherapy 《 Food and Drug Administration Safety and Innovation Act》 (Gesetz über die Sicherheit und Innovation der Food and Drug Administration). The status so the development and management of the drug treatment will cover the diseases and cover an erheblichen undecoverten medical condition. The diagnosis of the medical treatment is that the FDA leadership for the clinical treatment exists, the clinical treatment is carried out in Australia and the time for the market research during the treatment if there is a bad treatment zen expensive.